RPCEC00000037
Completed
Phase 2
Clinical trial of Dermatophagoides pteronyssinus allergenic extract (VALERGEN-DP), for subcutaneous therapeutic use in asthmatic adults sensitive to this allergen.
ational Biopreparations Center (BIOCEN)0 sitesDecember 9, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Bronchial asthma
- Sponsor
- ational Biopreparations Center (BIOCEN)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Asthmatic allergic patients with positive responses during the preliminary survey in the following aspects: family and personal history of atopy, clinical symptoms only triggered when exposed to dust at home, mainly indoors, when getting up in the morning or going to bed at night. 2\. Skin test positive to D. pteronyssinus allergenic extract, 20,000 BU/ml VALERGEN\-DP. The response to the allergen under study is predominant when compared to that obtained with other mites. 3\. Patients included in the study will be patients clinically diagnosed as extrinsic asthmatics who, in according to the clinical\-therapeutic identification booklet, are classified as mild or moderate persistent patients in keeping with the International Agreement on Asthma Diagnosis and Treatment. 4\. Age between 16 and 45 years. 5\. Any sex and race. 6\. Patients expressing their consent in writing to participate in our trial.
Exclusion Criteria
- •1\. Patients not giving their consent in writing (Model 6\) to participate in our trial. 2\. Patients on allergenic extract immunotherapy during the two preceding years. 3\. Patients classified as intermittent or severe persistent asthmatics after being interviewed. 4\. Patients with a diagnosed autoimmune disease of any kind. 5\. Generalized severe eczema. 6\. Patients with diagnosed tumoral disease. 7\. Patients on betablocker treatment. 8\. Patients with psychiatric disorders. 9\. Patients not cooperating with treatment. 10\. Patients who, at least one year before the study, needed immunostimulant or immunosuppressor treatment (no corticosteroids), including interferon and cyclosporine A. 11\. Pregnancy and breastfeeding. 12\. Adrenalin\-contraindicated patients (high blood pressure). 13\. Patients who, at least one year before the study, were under non\-conventional treatments such as: Vimang, Aloe, ozone, banana capsules.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy of VALERGEN-DP sublingual vaccine in asthmatic adults.Bronchial asthmaAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000034ational Biopreparations Center (BIOCEN)
Completed
Phase 2
Efficacy of VALERGEN-DP subcutaneous vaccine in asthmatic adultsBronchial asthmaAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000027ational Biopreparations Center (BIOCEN)
Completed
Phase 2
Evidence of the clinical efficacy of VALERGEN-DS vaccine in asthmatics.Bronchial asthmaAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000032ational Biopreparations Center (BIOCEN)
Completed
Phase 2
Efficacy of VALERGEN-DS sublingual vaccine in asthmatic adultsBronchial asthma.AsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000030ational Biopreparations Center (BIOCEN)
Completed
Phase 3
Efficacy of VALERGEN-DS subcutaneous vaccine in asthmatic adults.Bronchial asthmaAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000028ational Biopreparations Center (BIOCEN)